Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rolapitant

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

- PMLiVE

Sobi’s Gamifant receives final rejection from CHMP for primary HLH

Committee reiterated previous negative opinion

- PMLiVE

Novartis’ canakinumab failed to improve survival in COVID-19 study

Swiss pharma company had been studying drug in hospitalised COVID-19 patients

- PMLiVE

Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

- PMLiVE

Novartis scores CHMP backing for cholesterol drug Leqvio

Potential first-in-class treatment moves closer to EU approval

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

J&J halts COVID-19 vaccine study after unexplained participant illness

Company convened data and safety monitoring board to review event

- PMLiVE

Phase 1/2a results for J&J’s COVID-19 vaccine show early promise

Vaccine produced neutralising antibodies in 98% of participants

AstraZeneca AZ

EU will shoulder certain liability costs in AZ COVID-19 vaccine deal

Low-cost deal will see the EU assume responsibility for side-effect claims

- PMLiVE

J&J advances COVID-19 vaccine into phase 3 testing

News comes after last week's announcement from Novavax on its launch of a UK-based phase 3 trial

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links